The contracts are for two lateral flow rapid antigen tests, a laboratory-based test to detect and identify SARS-CoV-2 variants, and a rapid RT-PCR test.
Avacta said that the deal will enable scientists to perform a laboratory test to detect the SARS-CoV-2 spike protein and some of its dominant variants.
For the three months ended March 31, the firm said that preliminary revenues for Q1 are expected to be $1.4 million compared with $3.2 million a year ago.
The firm said it has licensed an instrument-free rapid immunoassay from an undisclosed test manufacturer that has received FDA Emergency Use Authorization.
The UK government said that everyone in England will be able to access free lateral flow testing for SARS-CoV-2 twice a week to support the reopening of society.
The test runs on DiaSorin's Liaison XL Analyzer and may be used by any lab CLIA-certified to perform moderate- or high-complexity tests, according to the FDA.
The third-party consulting group used for the analysis recommended using a survey to set Medicare payment rates to reduce the reporting burden on laboratories.
The test can be used in conjunction with other FDA-cleared Lyme enzyme immunoassays developed by GSD as part of a CDC-recommended modified two-tiered testing algorithm.
The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.
The coalition includes partners from all over the world, including universities, research centers, and health systems in South Asia, Africa, South America, and the US.
The firm said it believes that the results of a recent study are representative of the broader utility of the test and its potential for broad application to diagnose concussions.
The company said the test can be used to evaluate effective antibody levels after SARS-CoV-2 infection or vaccination, as well as to assess adaptive immunity.
The assay is Guardant Health’s first commercially available product for clinical management of early-stage tumors and is initially focused on colorectal cancer.
The firm's assay leverages reverse transcriptase quantitative PCR to amplify two separate regions of the HIV-1 genome to monitor HIV-infected patients.
